Rare reports of pancytopenia, agranulocytosis, and leukopenia have been seen in patients treated with Trileptal during postmarketing experience. Discontinuation of the drug should be considered if ...

PharmD Trileptal (oxcarbazepine) is an anticonvulsant drug approved by the U.S. Food and Drug Administration (FDA) to treat ...